Interchangeability

Grundfos Launches New SE Range 48 1.5-15Hp Heavy Duty Wastewater Submersible Pumps

Retrieved on: 
Mardi, avril 30, 2024
Green Technology, Manufacturing, Environment, Other Technology, Sustainability, Building Systems, Environmental Health, Other Construction & Property, Technology, Other Energy, Construction & Property, Utilities, Agriculture, Natural Resources, Energy, Other Manufacturing, Machinery, Engineering, Interchangeability, Clogging, Sanitation, Water, Cartridge, Risk

Grundfos , a global leader in water technology and services, announced today a new SE range 48 1.5-15Hp wastewater submersible pumps for handling large amounts of wastewater, process water and unscreened raw sewage in heavy-duty municipal, utility and industrial applications.

Key Points: 
  • Grundfos , a global leader in water technology and services, announced today a new SE range 48 1.5-15Hp wastewater submersible pumps for handling large amounts of wastewater, process water and unscreened raw sewage in heavy-duty municipal, utility and industrial applications.
  • The Grundfos SE range 48 1.5-15Hp pumps are available with efficient single-channel or SuperVortex impellers allowing for free passage of solids up to 4 inches.
  • “With the introduction of the Grundfos SE range 48 1.5-15Hp submersible pumps, we are setting new benchmarks in sanitation, water contamination prevention, and the secure processing of wastewater.”
    The Grundfos SE range 48 1.5-15Hp submersible wastewater pumps are ideal for intermittent operation and can also be dry-installed without the need for external motor cooling.
  • Grundfos SE range 48 1.5-15Hp pumps are available now.

VIAVI Launches Industry's First Single, Duplex and Multi-Fiber Probe Microscope with Complete Automated Workflow

Retrieved on: 
Mardi, mars 12, 2024
Optics, Conference, Interchangeability, Batman: Gotham Knight, INX, Printed circuit board

CHANDLER, Ariz., March 12, 2024 /PRNewswire/ -- VIAVI Solutions Inc. (VIAVI) (NASDAQ: VIAV) today expanded its fiber optic test solutions portfolio with the addition of the INX™ 760 probe microscope.

Key Points: 
  • CHANDLER, Ariz., March 12, 2024 /PRNewswire/ -- VIAVI Solutions Inc. (VIAVI) (NASDAQ: VIAV) today expanded its fiber optic test solutions portfolio with the addition of the INX™ 760 probe microscope.
  • The first fully automated probe microscope on the market, the INX 760 delivers the industry's fastest inspection and analysis of single, duplex and multi-fiber connectors in applications ranging from hyperscale data centers, metro core construction, telco distribution and more.
  • The INX 760 will be showcased at the Optical Fiber Communication (OFC) Conference and Exposition from March 26-28, 2024 in San Diego, California.
  • The INX 760 automates every step of the inspection process, from test setup and tip configuration to image focus, analysis and data storage.

Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
Samedi, mars 9, 2024
EMA, Week, Psoriasis, Committee, SB5, Political moderate, Ustekinumab, Organon, FDA, Food, Samsung, BLA, Trial of the century, AAD, Safety, CHMP, Pharmacokinetics, Abstract, Biologics license application, American Academy, Novartis, Interchangeability

“We are excited to present new clinical data for our immunology portfolio at AAD Annual Meeting.

Key Points: 
  • “We are excited to present new clinical data for our immunology portfolio at AAD Annual Meeting.
  • The high-concentration (40 mg/0.4 mL) formulation of prefilled syringe and prefilled autoinjector of HADLIMA was approved in August 2022.
  • The study showed that efficacy, safety, and immunogenicity between the three arms were comparable up to Week 52.
  • Details of the Samsung Bioepis’ abstracts are as follows:
    Clinical Similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis: Randomized, Double-blind, Phase III, 52-Week Results

Exclusive Product Preview: WYBOT's Revolutionary Pool Maintenance Tech Unveiled

Retrieved on: 
Mercredi, janvier 10, 2024
Cloud, CES, Swimming, Consumer Electronics Show, S2, Interchangeability

WYBOTICS, having entered the swimming pool cleaning robot industry in 2005, continues to push boundaries with this innovative creation.

Key Points: 
  • WYBOTICS, having entered the swimming pool cleaning robot industry in 2005, continues to push boundaries with this innovative creation.
  • The S2 boasts internal high-precision sensors that enable it to cover the entire pool bottom, walls, and waterline with accuracy.
  • The WYBOT M2 takes pool cleaning to new heights with its revolutionary visual-based dirt identification system.
  • Cloud connectivity and remote control functions further elevate the M2's capabilities, providing users with unprecedented control over their pool maintenance.

Blues and RAKwireless Announce Partnership to Streamline IIoT Product Development

Retrieved on: 
Jeudi, octobre 26, 2023
Interchangeability, User experience, Industrial internet of things, Partnership, LoRa, Video game, Blues

Blues' Notecard is now available across RAKwireless' extensive portfolio of WisBlock modules, sensors and enclosures, simplifying global cellular connectivity for IIoT solutions.

Key Points: 
  • Blues' Notecard is now available across RAKwireless' extensive portfolio of WisBlock modules, sensors and enclosures, simplifying global cellular connectivity for IIoT solutions.
  • Together, Blues and RAKwireless will provide global customers with a simple and pre-configured cellular IIoT solution, Blues.ONE, and a composable WisBlock interface board, RAK13102.
  • "Our partnership with RAKwireless is revolutionary for IIoT advancement, bringing together Blues' scalability, security and simplicity, and the unique modularity of the WisBlock ecosystem.
  • With Blues' Notecard, RAKwireless' Blues.ONE and RAK13102 will simplify programming for engineers, allowing them to streamline IIoT product deployment," said Brandon Satrom, VP of Developer Experience and VP of Product at Blues.

Adalimumab-adbm, Boehringer Ingelheim's Interchangeable biosimilar to Humira®, now available at low wholesale acquisition cost

Retrieved on: 
Lundi, octobre 2, 2023
Interchangeability, Boehringer Ingelheim, Adalimumab, WAC, Canonical form, Acquisition, Syringe, Pharmaceutical industry

RIDGEFIELD, Conn., Oct. 2, 2023 /PRNewswire/ -- Boehringer Ingelheim announced today that Adalimumab-adbm injection, the company's interchangeable* biosimilar to Humira® (adalimumab), is now available at a low wholesale acquisition cost (WAC). Adalimumab-adbm is approved to treat multiple chronic inflammatory diseases and will be priced at an 81% discount to Humira. It is also available under the brand name Cyltezo®, which launched in July 2023 and is priced at a 5% discount to Humira.

Key Points: 
  • RIDGEFIELD, Conn., Oct. 2, 2023 /PRNewswire/ -- Boehringer Ingelheim announced today that Adalimumab-adbm injection, the company's interchangeable* biosimilar to Humira® (adalimumab), is now available at a low wholesale acquisition cost (WAC).
  • Adalimumab-adbm is approved to treat multiple chronic inflammatory diseases and will be priced at an 81% discount to Humira.
  • It is also available under the brand name Cyltezo®, which launched in July 2023 and is priced at a 5% discount to Humira.
  • *Interchangeable for the conditions of use, strengths, dosage forms, and routes of administration described in its full Prescribing Information .

ATHLETICA SPORT SYSTEMS INC. AND LEDFOIL REVOLUTIONIZE ICE RINK ADVERTISING WITH UNDER-ICE LED SCREENS

Retrieved on: 
Lundi, juillet 24, 2023
Interchangeability, Advertising, Partnership, LED, Ice, Mobile phone

WATERLOO, ON and HELSINKI, July 24, 2023 /PRNewswire/ - LedFoil and Athletica Sport Systems Inc. are pleased to announce a strategic partnership that will fundamentally change the game of ice rink advertising.

Key Points: 
  • WATERLOO, ON and HELSINKI, July 24, 2023 /PRNewswire/ - LedFoil and Athletica Sport Systems Inc. are pleased to announce a strategic partnership that will fundamentally change the game of ice rink advertising.
  • The LedFoil LED screen technology turns static under-ice advertisements into moving visual content, e.g.
  • The vast variety of content playable on under-ice LED screens allows us to elevate the entire experience to a whole new level", said Andrew McRae, Chief Executive Officer of Athletica Sport Systems.
  • Athletica Sport Systems Inc. is the only provider of the service in North America.

Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.

Retrieved on: 
Samedi, juillet 1, 2023
Crohn's & Colitis Foundation, National Psoriasis Foundation, Psoriatic arthritis, Interchangeability, Arthritis Foundation, Food and Drug Administration, Dermatology, Quality of life, American Academy, Colitis, Psoriasis, Crohn's disease, Boehringer Ingelheim, Patient, Risk, Phase, FDA, Health, Safety, Food, Management of Crohn's disease, Rheumatoid arthritis, Disease, Generic drug, Pharmaceutical industry, Adalimumab

Cyltezo was approved as an Interchangeable biosimilar in 2021, and is available as a prefilled syringe, or as a Cyltezo® Pen autoinjector.

Key Points: 
  • Cyltezo was approved as an Interchangeable biosimilar in 2021, and is available as a prefilled syringe, or as a Cyltezo® Pen autoinjector.
  • "Cyltezo is the first and only FDA-approved Interchangeable biosimilar to Humira® that is available to the millions of people in the U.S. living with certain chronic inflammatory diseases," said Stephen Pagnotta, Executive Director and Biosimilar Commercial Lead at Boehringer Ingelheim.
  • An Interchangeable biosimilar must first meet the high FDA standards of a biosimilar.
  • "For many people living with plaque psoriasis or psoriatic arthritis, finding effective relief from symptoms can be a daily struggle.

Mattermost Introduces “OpenOps” to Speed Responsible Evaluation of Generative AI Applied to Workflows

Retrieved on: 
Mercredi, juin 28, 2023
Graphics processing unit, Mattermost, LLM, Microsoft Teams, Collection, AIS, APACHE II, PALO, Safety, Interchangeability, Synthetic media, Microsoft, Research, Hugging Face, MIT, OpenAI, IP, Architecture, Apache, App Store (iOS/iPadOS), Free and open-source software, Organization, Falcon, Production, Risk, Learning, Generative, AI, Azure, Question, Environment, Conference, Automation, Medical device, Online shopping, Customer service, Trust

PALO ALTO, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- At the 2023 Collision Conference, Mattermost, Inc., the secure collaboration platform for technical teams, announced the launch of “OpenOps”, an open-source approach to accelerating the responsible evaluation of AI-enhanced workflows and usage policies while maintaining data control and avoiding vendor lock-in.

Key Points: 
  • AI Bots with Interchangeable AI Backends: OpenOps enables AI bots to be integrated into operations while connected to an interchangeable array of AI platforms.
  • For maximum performance, tap into third-party AI frameworking including OpenAI ChatGPT, the Azure AI Platform and Anthropic Claude.
  • This allows organizations to develop a rich corpus of real-world training data for future AI backend evaluation and fine-tuning.
  • The system also removes the need for specialized hardware such as GPUs, broadening the number of developers who can explore self-hosted AI models.

Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients

Retrieved on: 
Vendredi, juin 23, 2023
Science, Interchangeability, Boehringer Ingelheim, FDA, Pharmacy, Physician, Medicine, Patient, UnitedHealth Group, Rare-earth element, Generic drug, Adalimumab

Cyltezo is an FDA-approved Interchangeable biosimilar to Humira® (adalimumab) and was initially approved in 2017.

Key Points: 
  • Cyltezo is an FDA-approved Interchangeable biosimilar to Humira® (adalimumab) and was initially approved in 2017.
  • "Optum Rx's decision to add Cyltezo to its formulary could benefit millions of Americans, improving access to a crucial medicine that has been a safe and effective treatment for many inflammatory conditions for the last two decades," said Stephen Pagnotta, Executive Director and Biosimilar Commercial Lead at Boehringer Ingelheim.
  • "We are proud to bring our many decades of experience in complex biologics to the biosimilar space, enabling physicians and patients to feel confident in the science, Interchangeability and manufacturing of Cyltezo."
  • Cyltezo will be commercially available in the U.S. on July 1, 2023.